Biotechnology and Pharmaceuticals · asia
AI-Assisted Target Discovery and Molecular Design Reach Phase III: New Pulmonary Fibrosis Drug Begins Large Trial in China
Rentosertib has advanced from the AI-ranked TNIK target to a 320-patient pivotal trial, which will use changes in lung function over one year to test whether the early signal holds; this is also the most rigorous clinical test yet of a drug whose foundational design involved algorithms.
A drug whose therapeutic target was selected with the help of artificial intelligence, which then also participated in molecular generation and optimization, is entering the decisive stage of clinical development. Insilico Medicine has initiated a Phase III trial of rentosertib in China, aiming to slow the irreversible loss of lung function in patients with idiopathic pulmonary fibrosis. What is truly being tested is not only a single drug candidate, but also whether AI-driven drug development can produce a treatment with clinical value.
According to company announcements and Hong Kong Stock Exchange filings, this prospective, randomized, double-blind, placebo-controlled trial is expected to enroll approximately 320 patients at 47 centers in China. Participants will take rentosertib or placebo daily for 52 weeks; the primary endpoint is the annual decline in forced vital capacity (FVC), meaning how the total volume of air that patients can forcibly exhale changes over time. Secondary measures include time to first disease worsening, the lungs’ gas-exchange capacity, and questionnaire-assessed quality of life.
Rentosertib is an oral small-molecule TNIK inhibitor. The company says its PandaOmics system integrates multi-omics data from fibrotic tissue, biological networks, causal inference, literature, and patent information, and identified TNIK—which is involved in multiple fibrosis- and inflammation-related signaling pathways—as a candidate target; another generative chemistry platform, Chemistry42, was used to generate and optimize molecular structures. AI’s role here is as a tool for narrowing the scope of target discovery and chemical design. Whether the drug is effective must still be confirmed step by step through experiments, human trials, and regulatory review.
The basis for advancing to Phase III comes from a peer-reviewed Phase IIa trial. The study enrolled 71 patients at 22 centers in China and assigned them to placebo or one of three rentosertib dosing regimens for 12 weeks of treatment. The study met its objectives focused primarily on safety and tolerability; the company reported that mean FVC increased by 98.4 milliliters in the 60-milligram once-daily group, while it declined by 20.3 milliliters in the placebo group, with a lung-function signal that varied by dose.
These results cannot yet be regarded as conclusive evidence of efficacy. The Phase IIa trial had a small sample and short observation period, and the lung-function analysis was not a primary endpoint sufficient to directly demonstrate long-term clinical benefit; baseline differences between groups and statistical uncertainty also limit interpretation. By extending treatment to one year and expanding enrollment, the Phase III trial is intended to determine whether the early difference can be reproduced across more patients and different hospitals, while more fully identifying long-term adverse events.
Background
Idiopathic pulmonary fibrosis causes lung tissue to gradually thicken, stiffen, and develop scarring, leading to a continuing decline in patients’ ability to breathe. Existing antifibrotic treatments can slow deterioration but cannot reverse fibrosis that has already formed, so a new drug must demonstrate that it can deliver sufficient and durable additional benefit within the existing treatment landscape. Rentosertib received orphan drug designation from the U.S. Food and Drug Administration in 2023 and breakthrough therapy designation from China’s Center for Drug Evaluation in 2025, but these designations are intended to facilitate development and review and are not equivalent to marketing authorization.
The trial is currently registered under the numbers CTR20262475 and NCT07687459, with Xu Zuojun of Peking Union Medical College Hospital serving as principal investigator and Zhong Nanshan and Chen Chang, president of Shanghai Pulmonary Hospital, jointly leading the study. Rentosertib remains an investigational drug and has not been approved to treat idiopathic pulmonary fibrosis; until the Phase III efficacy, safety, and complete data are released, “AI-discovered” describes the development pathway, not a guarantee of clinical success.